| Followers | 22 |
| Posts | 3351 |
| Boards Moderated | 0 |
| Alias Born | 01/17/2013 |
Tuesday, November 05, 2013 1:28:32 PM
Bull, the grant were awarded to advanomics , perhaps why we are not seeing the capital trickle to sbfm.
IMHO this will be all merged in one, thus the corporate re domicile.
Advanomics, the parent company of Sunshine Biopharma, has received $510,000 research grant from Canadian Institutes of Health Research (CIHR), to advance the development of Adva-27a, an anticancer drug compound for multidrug resistant tumours.
The grant was awarded jointly to Advanomics and its collaboration partner, Ecole Polytechnique.
Sunshine Biopharma CEO Dr Steve Slilaty said that they are extremely pleased to have garnered the support from CIHR in addition to the support from NSERC and NanoQuebec to develop their novel cancer drug.
"Their commitment will prove invaluable in the advancement of Adva-27a and provides us a strong foundation for clinical trials," Dr Slilaty added.
Adva-27a, which is currently in the IND-enabling development stage, was found to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancers cells.
http://contractresearch.pharmaceutical-business-review.com/news/advanomics-wins-research-grant-for-cancer-drug-candidate-130813
IMHO this will be all merged in one, thus the corporate re domicile.
Advanomics, the parent company of Sunshine Biopharma, has received $510,000 research grant from Canadian Institutes of Health Research (CIHR), to advance the development of Adva-27a, an anticancer drug compound for multidrug resistant tumours.
The grant was awarded jointly to Advanomics and its collaboration partner, Ecole Polytechnique.
Sunshine Biopharma CEO Dr Steve Slilaty said that they are extremely pleased to have garnered the support from CIHR in addition to the support from NSERC and NanoQuebec to develop their novel cancer drug.
"Their commitment will prove invaluable in the advancement of Adva-27a and provides us a strong foundation for clinical trials," Dr Slilaty added.
Adva-27a, which is currently in the IND-enabling development stage, was found to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancers cells.
http://contractresearch.pharmaceutical-business-review.com/news/advanomics-wins-research-grant-for-cancer-drug-candidate-130813
Recent SBFM News
- Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year • ACCESS Newswire • 04/06/2026 12:30:00 PM
- Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea • ACCESS Newswire • 10/28/2025 11:45:00 AM
- Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline • ACCESS Newswire • 10/20/2025 11:45:00 AM
- Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin • ACCESS Newswire • 10/16/2025 11:45:00 AM
- Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience • ACCESS Newswire • 10/14/2025 11:00:00 AM
- Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections • ACCESS Newswire • 10/09/2025 12:00:00 PM
